KFAS
FULC icon

Keating Financial Advisory Services’s Fulcrum Therapeutics FULC Stock Holding History

Keating Financial Advisory Services’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23 Sell
3
-21
-88% -$195 ﹤0.01% 2501
2025
Q4 		$271 Buy
+24
New +$244 ﹤0.01% 2033

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Keating Financial Advisory Services's FULC Position: Q1 2026 in Review

Keating Financial Advisory Services reduced its Fulcrum Therapeutics (FULC) stake by 88% in Q1 2026, selling an estimated $195 and leaving 3 shares worth $23. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Keating Financial Advisory Services first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. The position peaked at $271 in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Keating Financial Advisory Services held 3 shares of Fulcrum Therapeutics worth $23 as of Q1 2026.
  • Keating Financial Advisory Services sold 21 Fulcrum Therapeutics shares in Q1 2026, an estimated $195.
  • Fulcrum Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #2501 holding.
  • Keating Financial Advisory Services first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Fulcrum Therapeutics position peaked at $271 in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.